Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Excerpt from Barron’s article today:
“One of the most important problems is qualifying the production of parts,” Claus Emmelmann, head of Germany’s Fraunhofer Institute tells Barron’s. His institute is dedicated to expanding the use of metal-based additive manufacturing in industry. He says the development process for designing and qualifying satisfactory parts is expensive and time consuming. “We are bashing our way to calibrating and qualifying parts through repeated failures.”
That’s where Rice’s Sigma comes in. The small New Mexico-based company sells products to improve quality and validate parts. They are the quality control of the 3-D printing world.
“You can overheat or under melt parts,” says Rice, explaining all the other things that can go wrong while a laser melts metal powder. Variability is the enemy of production. Manufacturers want consistent parts fast. “3-D printers have personality,” adds Rice.
His company uses software and artificial intelligence to scan and adjust welding characteristics in real time. “Sigma truncates the part [validation] process significantly,” says Emmelmann.
“One of the most important problems is qualifying the production of parts,” Claus Emmelmann, head of Germany’s Fraunhofer Institute tells Barron’s. His institute is dedicated to expanding the use of metal-based additive manufacturing in industry. He says the development process for designing and qualifying satisfactory parts is expensive and time consuming. “We are bashing our way to calibrating and qualifying parts through repeated failures.”
That’s where Rice’s Sigma comes in. The small New Mexico-based company sells products to improve quality and validate parts. They are the quality control of the 3-D printing world.
“You can overheat or under melt parts,” says Rice, explaining all the other things that can go wrong while a laser melts metal powder. Variability is the enemy of production. Manufacturers want consistent parts fast. “3-D printers have personality,” adds Rice.
His company uses software and artificial intelligence to scan and adjust welding characteristics in real time. “Sigma truncates the part [validation] process significantly,” says Emmelmann.
Yes and John Rice gets quoted a couple of times about validation of parts.
Not his company but former company, who wanted to merge with and was spurned so makes sense.
No news but at least we finally turned green.
We have heard nothing from Emisphere, everything we hear is from Novo Nordisk.
Crickets
Yes, I think it’s due to darkness. I don’t understand why they haven’t announced the milestone payment which they should have received but Rubino is gone now so just a shell of a company. I still think it’s worth more $ but may be proved wrong. Volume was heavy yesterday on the downside.
Well you made a great decision!
Can’t blame you, the only news we get is from Novo Nordisk as a partner. The way this is being walked back down you may get a nice point to re-enter if you choose.
Hoping to see a PR on the $10M milestone payment and how it will be used. Darkness causes this to walk back down but has held up pretty well.
No, waiting pattern. Should hear this week about FDA approval.
No problem
$20 but originally was $10. I’m in a wait and see really think we could see $30, Novo is investing significantly in this and has studies going to 2024 plus they just purchased another priority review voucher so interesting time ahead.
No way to know but Novo just had a pretty bullish conference call and earnings press release. They said they expect approval by 9/20.
Novo filed for approval in Japan, not much else. Waiting for Sept or earlier FDA approval.
Not meaningless as it is a patent but close to it given this company’s track record.
I do agree that stock is getting a little rich but FDA approval in 4 months, potential CVT approval 8 months. Novo is already working on improved formulation, they are starting lot’s of studies for obesity, kidney and retina problems, etc so Novo really sees this as a potential wonder drug. Also, EMA, Canadian approvals are in pipeline.
You need to forward to the 28 min mark.
Milestone payments will come with FDA and MMA approvals, possible new agreement in 6 to 12 months, and still exploring an agreement for B12
You can listen to it as it’s still available. Go to about 28 min mark for start
https://east.virtualshareholdermeeting.com/vsm/web?pvskey=EMIS2019
Yes, May 30 10AM. Listed in your proxy materials.
May 30, 1AM. Webinar
Not approval just filing for approval in Europe. Everything continues to move forward.
Move with some volume which is even better!
Big News - All 10 studies are out now
http://ir.emisphere.com/node/14936/pdf
They exclusivity on four molecules I believe.
Novo presents at ADA on Sunday but probably nothing in addition to this.
Nice move today
Interesting stuff, they obviously know the outcome of these recent studies and with locking in the exclusivity maybe they see acceleration of this. Hopefully, we finally realize a big pay day!